Mildronate: Cardioprotective action through carnitine-lowering effect

Maija Dambrova; Edgars Liepinsh; Ivars Kalvinsh

doi:10.1016/S1050-1738(02)00175-5

Mildronate: Cardioprotective action through carnitine-lowering effect

Maija Dambrova, Edgars Liepinsh, Ivars Kalvinsh

Research output: Contribution to journal › Review article › peer-review

125 Citations (Scopus)

Abstract

Mildronate [3-(2,2,2-trimethylhydrazinium)propionate dihydrate] ameliorates cardiac function during ischemia by modulating myocardial energy metabolism. Biochemical and pharmacological evidence supports the hypothesis that the mechanism of action of mildronate is based on its regulatory effect on carnitine concentration, whereby mildronate treatment shifts the myocardial energy metabolism from fatty acid oxidation to the more favorable glucose oxidation under ischemic conditions. Because mildronate treatment prepares cellular metabolism and membrane structures to survive ischemic stress conditions, it is possible that mildronate could be regarded as an agent of pharmacological preconditioning.

Original language	English
Pages (from-to)	275-279
Number of pages	5
Journal	Trends in Cardiovascular Medicine
Volume	12
Issue number	6
DOIs	https://doi.org/10.1016/S1050-1738(02)00175-5
Publication status	Published - Aug 2002
Externally published	Yes

Field of Science*

3.1 Basic medicine

Publication Type*

1.1. Scientific article indexed in Web of Science and/or Scopus database

Access to Document

10.1016/S1050-1738(02)00175-5

Cite this

@article{22f7843478e74b688e8797703648f682,

title = "Mildronate: Cardioprotective action through carnitine-lowering effect",

abstract = "Mildronate [3-(2,2,2-trimethylhydrazinium)propionate dihydrate] ameliorates cardiac function during ischemia by modulating myocardial energy metabolism. Biochemical and pharmacological evidence supports the hypothesis that the mechanism of action of mildronate is based on its regulatory effect on carnitine concentration, whereby mildronate treatment shifts the myocardial energy metabolism from fatty acid oxidation to the more favorable glucose oxidation under ischemic conditions. Because mildronate treatment prepares cellular metabolism and membrane structures to survive ischemic stress conditions, it is possible that mildronate could be regarded as an agent of pharmacological preconditioning.",

author = "Maija Dambrova and Edgars Liepinsh and Ivars Kalvinsh",

note = "Funding Information: This work was supported by a grant from the Latvian Science Council. M.D. was supported by a stipend from the Swedish Heart and Lung Foundation.",

year = "2002",

month = aug,

doi = "10.1016/S1050-1738(02)00175-5",

language = "English",

volume = "12",

pages = "275--279",

journal = "Trends in Cardiovascular Medicine",

issn = "1050-1738",

publisher = "Elsevier Inc.",

number = "6",

}

TY - JOUR

T1 - Mildronate

T2 - Cardioprotective action through carnitine-lowering effect

AU - Dambrova, Maija

AU - Liepinsh, Edgars

AU - Kalvinsh, Ivars

N1 - Funding Information: This work was supported by a grant from the Latvian Science Council. M.D. was supported by a stipend from the Swedish Heart and Lung Foundation.

PY - 2002/8

Y1 - 2002/8

N2 - Mildronate [3-(2,2,2-trimethylhydrazinium)propionate dihydrate] ameliorates cardiac function during ischemia by modulating myocardial energy metabolism. Biochemical and pharmacological evidence supports the hypothesis that the mechanism of action of mildronate is based on its regulatory effect on carnitine concentration, whereby mildronate treatment shifts the myocardial energy metabolism from fatty acid oxidation to the more favorable glucose oxidation under ischemic conditions. Because mildronate treatment prepares cellular metabolism and membrane structures to survive ischemic stress conditions, it is possible that mildronate could be regarded as an agent of pharmacological preconditioning.

AB - Mildronate [3-(2,2,2-trimethylhydrazinium)propionate dihydrate] ameliorates cardiac function during ischemia by modulating myocardial energy metabolism. Biochemical and pharmacological evidence supports the hypothesis that the mechanism of action of mildronate is based on its regulatory effect on carnitine concentration, whereby mildronate treatment shifts the myocardial energy metabolism from fatty acid oxidation to the more favorable glucose oxidation under ischemic conditions. Because mildronate treatment prepares cellular metabolism and membrane structures to survive ischemic stress conditions, it is possible that mildronate could be regarded as an agent of pharmacological preconditioning.

UR - http://www.scopus.com/inward/record.url?scp=0036701588&partnerID=8YFLogxK

U2 - 10.1016/S1050-1738(02)00175-5

DO - 10.1016/S1050-1738(02)00175-5

M3 - Review article

C2 - 12242052

AN - SCOPUS:0036701588

SN - 1050-1738

VL - 12

SP - 275

EP - 279

JO - Trends in Cardiovascular Medicine

JF - Trends in Cardiovascular Medicine

IS - 6

ER -

Mildronate: Cardioprotective action through carnitine-lowering effect

Abstract

Field of Science*

Publication Type*

Access to Document

Other files and links

Fingerprint

Cite this